The serine-threonine kinases Aurora A (AURKA) and p21-activated kinase 1 (PAK1) are frequently overexpressed in breast tumors and associated with aggressive tumor phenotypes and poor clinical outcomes [1–4]. The gene discussed is MARK2; the disease is breast neoplasm.